Angiogenesis is an indispensable prerequisite for the progression and metastasis of solid malignancies. Tumor angiogenesis appears to be governed by alterations of tumor suppressor or oncogenes operant in a broad range of tumors. We have addressed this issue in neuroblastoma, a malignancy characterized by the near-exclusive ampli®cation and overexpression of the N-Myc oncogene. Here, we report that N-Myc overexpression results in down-regulation of interleukin-6 (IL-6) and that IL-6 is an inhibitor of endothelial cell proliferation and VEGF-induced rabbit corneal angiogenesis. STAT3 is instrumental for IL-6 activity as infection with adenoviruses expressing a phosphorylation de®cient STAT3 mutant renders endothelial cells insensitive to the antiproliferative action of IL-6. Finally, though IL-6 does not in¯uence neuroblastoma cell growth, IL-6-expressing xenograft tumors in mice exhibit reduced neovascularization and suppressed growth. Our data shed new light on the mechanisms by which N-myc oncogene ampli®cation enhances the malignant phenotype in neuroblastomas.
Introduction
Angiogenesis, the generation of new capillaries from pre-existing vessels, is a tightly regulated and selflimited physiological process. Uncontrolled production of vessels plays an important role in the pathogenesis of many diseases, including progression of solid tumors. Indeed, the pattern of new blood vessel growth in human cancer and transgenic mouse models argues for the existence of an angiogenic switch, which is an essential part of the phenotypic repertoire that characterizes the successful tumor (Hanahan and Folkman, 1996) . As pathological angiogenesis derives from an imbalance between angiogenic factors and inhibitors (Hanahan and Folkman, 1996; Liotta et al., 1991) , it is therefore conceivable that the genetic changes of cancer could initiate angiogenesis by disturbing this balance in the tumor vicinity. Indeed, normal p53 regulates the expression of the angiogenesis inhibitors thrombospondin (TSP-1) (Dameron et al., 1994) and glioma-derived angiogenesis inhibitory factor (GD-AIF) (Van Meir et al., 1994) . Also, activation of oncogenes, like ras, has been shown to cause both upregulation of the expression of angiogenesis stimulators, like bFGF or VEGF, and down-regulation of angiogenesis inhibitors such as TIMP and TSP-1 (Bouck et al., 1996) .
Ampli®cation of N-myc oncogene is a frequent event in advanced stages (III and IV) of human neuroblastomas (Brodeur et al., 1984) . N-myc ampli®cation correlates with poor prognosis (Grady-Leopardi et al., 1986) and enhanced vascularization (Meitar et al., 1996) of human neuroblastomas, suggesting that Nmyc oncogene could stimulate tumor angiogenesis and thereby enhance neuroblastoma progression. Indeed, stable transfection and 100-fold overexpression of NMyc in a neuroblastoma cell line (SH-EP) resulted in an enhanced malignant phenotype of the transfectants (WAC2) and the ability to form well vascularized tumors in nude mice (Schweigerer et al., 1990) .
We have previously screened conditioned media from SH-EP007 and WAC2 cells reasoning that dierentially expressed angiomodulators would strongly suggest that these molecules are regulated by N-myc oncogene providing information about the molecular mechanisms linking oncogene activation with initiation of tumor angiogenesis. We were able to demonstrate that three EC proliferation inhibitors present in SH-EP007 supernatants (SI.1, SI.2, and SI.3) were completely down-regulated in WAC2 cells (Fotsis et al., 1999) . In a further study, we have identi®ed SI.3 as being activin A and documented antiangiogenic properties for this TGF-family member (Breit et al., 2000) . The present study deals with the structural and functional characterization of SI.2.
Results

SI.2 is identical with IL-6
Puri®cation of SI.2 from SH-EP007 supernatants resulted in a major peak of inhibitory activity eluted at a concentration of 52% acetonitrile from a C-18 reverse-phase HPLC column (Figure 1a) . In SDS ± PAGE analysis, we observed some minor quantities of M r 55 ± 116 kDa proteins in addition to a major protein of M r 24 kDa (Figure 1b) . Since previous gel ®ltration experiments had revealed an M r of about 25 ± 30 kDa for the activity (data not shown), the 24 kDa band was excised from the gel and subjected to in-gel digestion followed by mass ®ngerprint analysis. Sequence analysis of the nine peptides obtained unequivocally identi®ed SI.2 as IL-6 (Table I) . The identity was fully con®rmed by Western blot analysis where the intensities of IL-6 immunoreactivity in the respective HPLC fractions correlated strongly with SI.2 activity (Figure 1c) . Also, SI.2 activity could be abrogated by speci®c neutralizing antibodies against IL-6 (Figure 1d ).
IL-6 expression is down-regulated by N-Myc
Detection and isolation of IL-6 in SH-EP007 cells (vs WAC2) suggested that N-Myc down-regulated IL-6. The fractions corresponding to the active peak of the HPLC column in a were pooled, lyophilized, separated on a 12.5% SDS-polyacrylamide gel under reducing conditions and stained with Coomassie blue. Left lane, molecular markers in kDa; right lane, pooled HPLC fractions. The 24 kDa band indicated by the arrow was used for sequencing of SI.2. (c) Analysis of active HPLC fractions for endothelial cell growth inhibition and correlation with IL-6 immunoreactivity. Top, 10 ml aliquots of the fractions 50 ± 55 of the HPLC column in a (diluted 1 : 100) were examined for their abilities to inhibit bFGF-stimulated proliferation of BBCE cells. Values represent the means of duplicate determinations and varied by less than 5% of the mean. Bottom, Aliquots of the same fractions were analysed by Western blot with goat anti-IL-6 antibodies. (d) Eect of neutralizing anti-IL-6 antibodies on endothelial cell growth inhibition induced by SI.2. BBCE cells were treated either with rhIL-6 or HPLC-puri®ed SI.2 fractions (1 : 100 dilution) alone or in combination with antibodies against IL-6. Cell numbers were determined in duplicate and varied by less than 5% of the mean. The results were expressed as per cent of controls (cells receiving only bFGF) Indeed, further correlation of N-Myc and IL-6 expression in 13 neuroblastoma cell lines, both at the mRNA and protein levels, showed inverse relationship (data not shown). To substantiate N-Myc-induced down-regulation of IL-6, we used promoter-reporter assays. Upon transfection of HeLa cells with a vector containing wild-type N-myc cDNA, IL-6 promoter activity was suppressed substantially (Figure 2a,b) . Transfection of N-myc mutants lacking the myc box domains MBI or MBII (mutants d1 ± 134, d20 ± 90 and d96 ± 140) or the DNA-binding (mutant d381 ± 395) or the helix ± loop ± helix leucine zipper regions (mutant d395 ± 464) resulted in an unabated suppression of IL-6 promoter-CAT activity (Figure 2a,b) . In contrast, NMyc mutants lacking both the basic region (BR) and helix ± loop ± helix leucine zipper regions (HLH-Zip) (mutant d350 ± 464) had an impaired ability to suppress promoter activity and N-Myc mutants lacking the ®rst 300 amino acids (including the MBI, MBII and EX2/ EX3 regions) had completely lost this ability ( Figure  2a,b) . Thus, N-Myc regions highly conserved among myc-box genes (MBI, MBII) are not necessary while a contiguous BR-HLH-Zip region is important with the central region of the N-Myc protein being decisive for its suppressive eects on the IL-6 promoter.
We have used HeLa cells because of low transfection eciency of SH-EP007 cells resulting in detection problems with the CAT reporter construct of the IL-6 promoter. Subsequent generation of IL-6 promoter constructs fused to the more sensitive luciferase reporter gene (Figure 2c ) allowed con®rmation of the suppressing eect of N-Myc on transcription of IL-6 promoter in SH-EP007 cells and de®ned domains involved in this eect (Figure 2d ). These data indicate an N-Myc-speci®c role in inhibiting IL-6 promoter activity.
IL-6 inhibits endothelial cell proliferation via the STAT3 pathway
We had identi®ed IL-6 due to its ability to inhibit an important partial step of angiogenesis, i.e., vascular endothelial cell proliferation. In agreement with this ®nding, in addition to bovine brain capillary ECs, recombinant human IL-6 (rhIL-6) inhibited the bFGFstimulated proliferation of aorta (BAE) and human dermal microvascular ECs (data not shown). At the concentrations used, rhIL-6 was not cytotoxic, as seen by microscopic evaluation and by the fact that cell densities never fell below those present at seeding.
IL-6 can mediate its eects by binding to speci®c cell surface receptors with subsequent phosphorylation of the transcription factor STAT3 at Tyr705. When rhIL-6 was added to BBCE cells, it was, in fact, able to phosphorylate STAT3 in a time-and concentrationdependent manner (Figure 3a and data not shown). Simultaneous administration of angiogenic factors such as bFGF and VEGF did not alter the phosphorylation pattern of STAT3 (data not shown).
We wished to determine whether or not the STAT3 pathway was necessary and crucial for the IL-6-induced inhibition of vascular endothelial cell proliferation. To that aim, we infected BBCE cells with recombinant adenoviruses containing various stat3 forms and investigated the ability of rhIL-6 to inhibit proliferation of the infected cells. rhIL-6 was able to In contrast, rhIL-6 was unable to substantially inhibit proliferation of BBCE cells transfected with the dominant-negative stat3 mutant (AD/DN). These eects were equally observed in BBCE cells stimulated by bFGF or VEGF ( Figure 3b ). In order to mediate its eects on cell proliferation, STAT3 must be translocated from the cytosol to the cell nucleus. Therefore, we examined the ability of rhIL-6 to induce nuclear STAT3 translocation in the BBCE infected cells by using confocal laser microscopy. In fact, IL-6 induced STAT3 translocation in the BBCE cells transfected with the control vector (AD) or the vector containing wild-type stat3 (AD/ WT), but not the dominant-negative stat3 mutant (AD/DN) ( Figure 3c) . These data clearly demonstrate that IL-6 inhibits vascular endothelial cell proliferation induced by major angiogenesis stimulators and that inhibition is mediated via the STAT3 pathway.
IL-6 inhibits VEGF-induced neovascularization in the rabbit cornea assay
To evaluate whether or not IL-6 inhibited angiogenesis in vivo, we used the rabbit cornea assay. Initial experiments, in which pellets containing 0.25 or 1.0 mg of rhIL-6 were implanted, revealed no macroscopic evidence of IL-6-induced in¯ammation. In two out of seven animals receiving 1 mg rhIL-6 pellets, we observed evidence of a mild angiogenic response (Figure 4a ). However, whereas pellets containing 0.25 mg of rhIL-6 had a minor eect, pellets containing 1.0 mg of rhIL-6 completely inhibited VEGF-induced angiogenesis completely as compared to control pellets (Figure 4b ). Thus, IL-6 inhibits VEGF-induced angiogenesis. IL-6-induced inhibition of endothelial cell proliferation is STAT3 dependent. BBCE cells were infected with either adenovirus carrying wild-type stat3 (AD/WT) or adenovirus carrying the dominant negative stat3 (AD/DN). Adenovirus vector itself (AD) as well as non-infected cells were used as control. Cells then received buer only or bFGF (2.5 ng/ml) or VEGF (30 ng/ml) in the presence (+) or in the absence (7) of rhIL-6 and [ 3 H]thymidine incorporation assay was performed. (c) IL-6 induced nuclear translocation of STAT3. BBCE cells were infected with AD, AD/WT or AD/DN and treated with rhIL-6 as it was described in Materials and methods. Phospho-STAT3 was visualized by confocal microscopy using speci®c antibody and FITCconjugated anti-rabbit secondary antibodies. Magni®cation bar: 21 mm Oncogene N-myc oncogene overexpression down-regulates IL-6 E Hatzi et al
IL-6 inhibits tumor angiogenesis and growth in xenograft tumorigenesis assays in mice
As demonstrated earlier, overexpression of N-myc oncogene down-regulates IL-6 expression. Though the eect of IL-6 on EC proliferation and corneal angiogenesis suggested an attenuating role of IL-6 on malignant transformation via inhibition of angiogenesis, the result did not exclude a direct autocrine inhibitory eect of IL-6 on neuroblastoma cell proliferation. Towards this end, rhIL-6 had no eect on the proliferation of various neuroblastoma cell lines, including SH-EP007, WAC2, NBL-S, Kelly cells, even at very high concentrations (Figure 5a and data not shown). The same results were obtained when we transfected WAC2 neuroblastoma cells with a vector containing the human IL-6 cDNA under the control of a CMV promoter (not down-regulated by N-Myc) as compared to cells transfected with the empty vector. IL-6-expressing (c3, c11 and c21) ( Figure 5b ) and control (cve-1 and cve-2) WAC2 clones had an unabated ability for rapid proliferation which was very similar to that of the parental WAC2 cells and clearly distinct from that of the low N-myc expressing SH-EP007 cells (Figure 5b) . Thus, forced overexpression of IL-6 in WAC2 cells did not inhibit their in vitro proliferation.
Yet, the fast growing IL-6 expressing WAC 2 clones (c3, c11, c21) did grow slower as mouse xenografts (compared to control cve-1 and cve-2 WAC2 clones) exhibiting reduced vascularization (Figure 5c ± f) . Indeed, 7 days following intradermal implantation in the¯anks of immune-de®cient mice, the weight of tumors derived from the IL-6 expressing WAC2 cells (c3, c11 and c21) was decreased in a statistically signi®cant manner compared to both control clones (cve-1 and cve-2) (Figure 5d) . Similarly, the tumor volumes were signi®cantly smaller for clones c3 and c21 on day 7 compared to vector controls (Figure 5e ). At the same time point (7 days), the number of capillaries was signi®cantly lower in the IL-6 clones compared to that of all the control clones (Figure 5c ). The slow growth of the IL-6 expressing WAC2 clones was still visible in a set of mice sacri®ed at 4 weeks (Figure 5f ).
Discussion
We have previously shown that neuroblastoma cell supernatants contained three EC proliferation inhibitors (SI.1, SI.2 and SI.3), the expression of which was dramatically down-regulated upon N-Myc overexpression (Fotsis et al., 1999) . In the present study, SI.2 activity was identi®ed as IL-6 on the basis of mass ®ngerprinting analysis of tryptic peptides. Moreover, using reporter assays, we conclusively show, for the ®rst time, that N-Myc overexpression dramatically down-regulates IL-6 promoter transcription. Though several genes have been shown to be regulated by the myc gene family members using various assays (Facchini and Penn, 1998; Grandori and Eisenman, 1997) including crosslinking (Mac et al., 2000) and cDNA microarrays (Guo et al., 2000) , the IL-6 gene has never been included in these lists. Initial transfection experiments with deletion mutants of the IL-6 promoter revealed that the smallest construct (7140/ +12) was still inhibited by N-Myc. This construct contained several characterized binding sites such as AP-1, NF-kB, RCE and GRE (Ray et al., 1990) , however, it is not known whether one or more of these elements or additional DNA sequences are involved in IL-6 promoter repression by N-Myc.
Indirect repression of IL-6 gene via some of the known N-Myc/Max regulated genes (Facchini and Penn, 1998 ) is excluded, as neither the HLH-Zip nor the BR deletion released the transcriptional repression by N-Myc (Blackwood and Eisenman, 1991; Prendergast and Zi, 1991) . Interestingly, simultaneous deletion of both BR and HLH-Zip domains abolished IL-6 promoter suppression. Perhaps, a contiguous BR-HLH-Zip domain is the binding site of regulatory proteins such as Ying Yang-1 (YY-1) (Shrivastava et al., 1993) , and the presence of either BR or HLH-Zip domains alone is sucient for such binding. Alternatively, the BR and HLH-Zip domains are required as part of two independent complexes that are both necessary for the repressive eect of N-Myc on IL-6 promoter.
Direct eect of N-Myc on the Inr element of the IL-6 promoter is unlikely as combined deletions of the MBI, MBII and HLH domains appeared to only minimally release the N-Myc repression (Lee et al., 1996) . However, a signi®cant contribution was assigned to the central area of N-Myc between amino acids 134 ± 300 which encompasses the interaction domain with Nmi (aa 177 to 298) (Bannasch et al., 1999) . Nmi is a predominantly cytoplasmic protein that can be . Cell numbers were determined at the indicated times and represent the means of duplicate determinations. (c ± f) Eect of IL-6 in human neuroblastoma xenografts. BALB/c nu/nu mice were injected intradermally by 1610 6 WAC2 cells transfected with an IL-6-containing vector (c3, c11, c21) or the empty control vector (cve-1, cve-2). Capillary numbers (c), weight (d) or volume (e, f) of the tumors derived from the IL-6-transfected cells were then determined after 7 (c ± e) or 28 (f) days and compared to those obtained from the control cells. Symbols (solid circle) represent dierent mice. Inserts indicate statistical signi®cance (P) Oncogene N-myc oncogene overexpression down-regulates IL-6 E Hatzi et al translocated to the nucleus where it augments STATdependent transcription in response to cytokines by interacting with STATs (except STAT2) and enhancing association of CBP/p300 to STATs (Zhu et al., 1999) . It is tempting to speculate that recruitment of N-Myc via Nmi to STAT or other transcriptional complexes or competition of N-Myc for Nmi might in¯uence transcription.
The JAK ± STAT pathway, activated by the IL-6R/ gp130 receptors, plays a central role in IL-6 signaling (Heinrich et al., 1998) . Concerning cell proliferation, activation of STAT3 can either induce cell proliferation via cyclin D1 overexpression inducing cell proliferation (Bromberg et al., 1998) or cause growth arrest by enhancing expression of p21 or p27 cell cycle inhibitors (Bellido et al., 1998; Kortylewski et al., 1999) . Indeed, we have also observed that proliferation of adrenal cortex (ACE) ECs were not aected by rhIL-6 (data not shown). In all cases, dominant negative mutants of STAT3 reverse the eects on proliferation (Bellido et al., 1998; Bromberg et al., 1998; Kortylewski et al., 1999) , indicating that the STAT3 pathway is the target of extensive crosstalk with other pathways. In the present study, infection of BBCE cells with adenoviruses expressing negative mutant STAT3 (Y705F) eectively reversed the inhibitory eect of IL-6 on bFGF and VEGF-induced proliferation. This result indicates an important role for STAT3 in modulating angiogenic responses of ECs. Some recent studies have shown that both bFGF (Megeney et al., 1996) and VEGF (Bartoli et al., 2000; Korpelainen et al., 1999) can induce STAT3 phosphorylation and this is an excellent point for crosstalk. However, we were unable to observe phosphorylation of STAT3 from either angiogenic factor. Perhaps, cyclical, recurrent or delayed phosphorylation as previously reported for bFGF phosphorylation of STAT3 might have been the reason (Megeney et al., 1996) .
Inhibition of VEGF-induced neovascularization in the rabbit corneal assay reserved a truly in vivo antiangiogenic function for this cytokine. Previous studies have suggested a stimulatory role of IL-6 on angiogenesis and vasculogenesis judging from the expression pattern of the cytokine in ovarian follicles, maternal decidua and murine brain (Fee et al., 2000 ; Motro et al., 1990) . Further xenograft tumorigenesis assays in mice, con®rmed a speci®c antiangiogenic eect of IL-6 that was actually translated into reduced tumor growth rates. Indeed, though in vitro proliferation of IL-6-expressing WAC2 clones was not substantially dierent from that of the parental and control WAC2 clones, their xenograft tumor growth rate was decreased and correlated with a statistically signi®cant reduction in the number of new capillaries. Previous overexpression of IL-6 cDNA in Lewis lung carcinoma cells did not alter the growth rate of syngeneic tumors (Ohe et al., 1993) suggesting that, indeed, IL-6 might play an important role in the balance of angiomodulators in the vicinity of N-myc ampli®ed neuroblastomas.
Taken together our results indicate that (i) IL-6 is an angiogenesis inhibitor and (ii) ampli®cation of N-myc in neuroblastomas, in addition to eecting cell proliferation, could potentially enhance malignant phenotype progression by activating the angiogenic switch via down-regulation of IL-6 expression. Thus, contrary to other cancers, where STAT3 needs to be constitutively activated for transformation and blockage of apoptosis, in N-myc ampli®ed neuroblastomas, silencing of STAT3 (via down-regulation of IL-6) might be required for activation of angiogenesis de®ning, perhaps, a novel, tumor-selective angiogenesis pathway. Alteration of the balance of stimulators and inhibitors of angiogenesis seem to participate also in the malignant transformation repertoire of other members of the Myc family. Indeed, c-Myc has been shown to down-regulate the promoter of thrombospondin-1, a strong angiogenesis inhibitor. These results await con®rmation in primary neuroblastoma tumors.
Materials and methods
Cell culture and cell proliferation assays
Dishes, media and recombinant growth factors were described earlier (Fotsis et al., 1997 (Fotsis et al., , 1999 . Cells were cultured as described earlier (Fotsis et al., 1997; Hiller et al., 1991; Schweigerer et al., 1990) . Collection of conditioned medium from SH-EP007 cells was carried out as mentioned N-myc oncogene overexpression down-regulates IL-6 E Hatzi et al before (Fotsis et al., 1999) . Cell proliferation assays using BBCE cells were previously described (Fotsis et al., 1997 (Fotsis et al., , 1999 . Human recombinant IL-6 (rhIL-6) and goat polyclonal anti-human IL-6 neutralizing antibodies were provided from R&D systems.
Chromatography, mass fingerprint analysis and microsequencing
Concentration of conditioned medium (47 liters), acidi®cation and SP-Sepharose Fast Flow (SSFF) chromatography were described earlier (Fotsis et al., 1999) . Fractions containing SI.2 were puri®ed through a second SSFF column (320 ml bed volume) using a salt gradient at lower pH (4.8) for increased resolution. The desalted and lyophilized active fractions were then dissolved in 0.25% tri¯uoroacetic acid (TFA)/dH2O and loaded onto a Bakerbond Wide-Pore C-18 reversed phase high performance liquid chromatography (HPLC) column (4.66250 mm; Malinckrodt Baker, Philipsburg, NJ, USA) equilibrated with 0.1% TFA. Bound material was eluted with linear gradients from 0 ± 30% acetonitrile in 10 min and 30 ± 60% acetonitrile in 45 min at a¯ow rate of 1 ml/min. Fractions of 1 ml were collected, lyophilized and resuspended in culture water. An aliquot (10 ml) was tested for activity on BBCE cell proliferation. The active fractions were separated on 12.5% SDSpolyacrylamide gel under reducing conditions. Protein bands were excised from the Coomassie blue stained gel, destained, reduced and alkylated with iodoacetamide, and digested with trypsin. The resulting peptides were subjected to mass spectroscopy analysis using an MALDI-TOF instrument (Voyager DE-STR, PerSeptive Biosystems). Peptide samples were prepared using dihydroxybenzoic acid as matrix. From the calibrated MS peptide mass map, a peak table list was generated omitting signals observed in the chemical background spectrum. This peak table list was used as input to search the SWISSPROT and NCBI protein databases for sequence similarities. All searches were carried out using the MS-Fit software program (by Clauser KR and Baker PR, UCSF). MS-Fit search results were checked regarding the MOWSE score, molecular mass, isoelectric point, species and percentage of matching masses.
Transfections and IL-6 promoter reporter assays
Full-length N-myc (pcDNA3-N-myc) was generated by PCR ampli®cation using pN-myc as template (a gift from M Schwab, German Cancer Research Center, Heidelberg, Germany) (Hiller et al., 1991) . All deletion mutants of Nmyc were generated from the above construct by ligation of PCR products. All constructs were sequenced. Transient transfections were performed, according to the manufacturer's instructions, using either eectene (Qiagen) or lipofectamine plus reagent (Invitrogen) for CAT and luciferase IL-6 promoter reporter constructs, respectively. A reporter CAT construct containing the 71200 to +15 promoter fragment of the human IL-6 (pIL6-CAT(71200/ +15)) was kindly provided by Dr Scala (University Federico II, Naples, Italy) (Ambrosino et al., 1997) . HeLa cells (5610 5 per 60 mm dish) were transfected with 0.4 mg of the pIL6-CAT (71200/+15) construct, alone or in combination with 0.4 mg of wild-type or mutated N-myc expression vectors, for 40 h. In each transfection a constant total DNA concentration was used. Cells were collected and analysed for CAT activity using a CAT-ELISA kit according to the manufacturer's instructions (Roche Molecular Biochemicals). Luciferase reporter assays were carried out in SH-EP 007 cells using identical conditions except that three dierent luciferase constructs of the human IL-6 promoter (pIL-6-Luc) were used (7840, 7417 and 7140 to +12) (Matsui et al., 1999) . Luciferase activity was analysed by a commercial kit (Promega) using a lumonometer (EG&G junior, Berthold) . In all transfections, 0.2 mg of b-galactosidase (b-gal) expression vector (CMV-b-gal) was constransfected as an internal control. The expression and nuclear localization of all constructs were determined by Western blot using a mouse anti-human N-Myc antibody (Cymbus Biotechnology LTD, Hants, NF).
The full-length human IL-6 cDNA, kindly donated by Dr Podacks (University of Miami, FL, USA) was subcloned into the XhoI site of a CMV promoter construct. WAC2 cells (70% con¯uent) were transfected with eectene using 1.8 mg of the IL-6 construct and 0.2 mg of a construct containing puromycin resistance gene (Clontech). Clones were selected in medium containing 0.7 mg/ml puromycin and expression of IL-6 was evaluated by Western blot analysis of supernatants using a goat anti-IL-6 antibody (R&D). Several independently derived clones were obtained for each construct. Control transfectants were generated using the empty CMV promoter construct.
Phosphorylation of STAT3 protein in BBCE cells
BBCE cells were seeded in 12-well plates (400 000 cells/well), cultured for 2 days in DMEM containing 0.5% NCS and STAT3 and phospho-STAT3 were detected as described in a kit purchased from New England-Biolabs.
Preparation of adenoviruses expressing STAT3 and [ 3 H]thymidine incorporation assays
Recombinant adenoviruses harboring wild-type (AD/WT) and dominant negative (Y705F) (AD/DN) Stat3 cDNAs as well as a control adenovirus carrying only the vector (AD) were prepared as previously (Kunisada et al., 1998) . Adenoviruses were ampli®ed in 293 cells. The eciency of infection and the expression of the proteins were monitored by immuno¯uorescence and Western blot analysis, respectively. BBCE cells grown to subcon¯uency in 24-well plates were infected with the adenoviruses at a multiplicity of infection of 3 : 1 (three plaque-forming units (pfu)/cell) for 8 h in full medium. The medium was renewed and various concentrations of rhIL-6 together with 2.5 ng/ml bFGF or 30 ng/ml VEGF were added for an additional 24 h. Then, 1 mCi/ml of [ 3 H]methyl-thymidine (ICN) was added to each of the wells for the last 4 h of the incubation. Culture medium was removed and the cells were ®xed with ice-cold 10% trichloroacetic acid for 20 min at 48C, washed three times with water and solubilized in 0.1 M NaOH overnight at 48C. The radioactivity was counted in a beta liquid scintillation counter.
Translocation of STAT3 to the nucleus was studied after infection of the cells with three plaque-forming units (pfu)/ cell for 8 h in full medium, allowing the expression for another 20 h and adding 20 ng/ml rh-IL-6 for 15 min. Then, the cells were ®xed and STAT3 and phospho-STAT3 were detected as described in a kit purchased from New EnglandBiolabs. A Leica TCS-SP confocal microscope was used.
Rabbit corneal neovascularization assay
Corneal assays were performed in New Zealand white rabbits (Charles River, Calco, Lecco, Italy) (Ziche et al., 1997) in accordance with the guidelines of the European Economic Oncogene N-myc oncogene overexpression down-regulates IL-6 E Hatzi et al Community for animal care and welfare (EEC Law No. 86/ 609) . Brie¯y, after being anesthetized with sodium pentothal (30 mg/kg), slow release pellets bearing test substances were implanted in micro pockets surgically produced in the lower half of the cornea. Subsequent daily observation of the implants was made with a slit lamp stereomicroscope without anesthesia. rhIL-6 was ®rstly tested per se to ascertain the possible angiogenic and/or in¯ammatory activity of the cytokine. Then the antiangiogenic activity of IL-6 was evaluated by implanting VEGF165 pellets (0.2 mg/pellet) in the corneal tissue in which high concentrations of rhIL-6 were produced by implanting rhIL-6 pellets for 10 days. rhIL-6 pellets (0.25 mg and 1 mg/pellet) were gently removed and substituted with VEGF pellets. The neovascular response was compared to corneas in which PBS-containing pellets had been implanted.
Xenograft experiments in mice
Adult (8 ± 10 weeks) female BALB/c nu/nu mice were used as host animals. For tumor growth rate evaluation, approximately 1.0610 6 of WAC2 transfectants in 10 ml of Ca 2+ -and Mg 2+ -free Hanks' balanced salt solution (HBSS) were inoculated intradermally in the¯anks of mice (Rofstad and Halsor, 2000) . Tumor volume (V) was calculated as V=(p/ 6)ab 2 , where a is the longer and b is the shorter of two perpendicular diameters, measured with calipers. The volume at 4 weeks after the cell inoculation was used as parameter for tumor growth rate. Tumor-induced angiogenesis was assessed by using an intradermal angiogenesis assay (Danielsen and Rofstad, 1998) . Inoculation of WAC2 transfectants was carried out as for the tumor growth rate evaluation and mice were killed on day 7 after the inoculation.
Statistical evaluation of data was performed by nonparametric analysis using the Mann ± Whitney test followed by ttest using SPSS 10.0 statistical software (SPSS Inc., Chicago, IL, USA). Two-sided tests and a signi®cance criterion of P50.05 were used.
